BACKGROUND: The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines proposed a classification for allergic rhinitis based on the duration of symptoms (intermittent or persistent) rather than on the time of allergen exposure (seasonal or perennial). There had been no placebo-controlled, randomized, clinical trial of desloratadine (DL) in patients with persistent allergic rhinitis to date. OBJECTIVES: To assess the efficacy and safety of DL in patients with persistent allergic rhinitis based on the ARIA classification. METHODS:Patients 12 years of age and older with persistent allergic rhinitis were assessed over 85 days of treatment with DL 5 mg once daily (n = 360) or placebo (n = 356). The primary endpoint was the AM/PM reflective total 5-symptom score (T5SS) averaged over days 1-29. Secondary endpoints included AM/PM instantaneous T5SS and individual symptoms, therapeutic response, symptom severity assessed by a visual analogue scale and quality of life. RESULTS: The mean reduction in AM/PM reflective T5SS was significantly greater with DL than placebo over days 1-29 (-3.76 vs. -2.87, p < 0.001) and on each individual day (p < 0.05). The mean AM instantaneous T5SS was significantly reduced with DL compared with placebo as early as day 2 (-1.90 vs. -1.46; p < 0.001). The therapeutic response and improvement in quality of life were significantly greater with DL than placebo (p < 0.001 for each). The frequency of treatment-related adverse events was low and similar between DL (10.0%) and placebo (8.4%). CONCLUSIONS: This study showed DL to be effective and safe in the treatment of persistent allergic rhinitis.
RCT Entities:
BACKGROUND: The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines proposed a classification for allergic rhinitis based on the duration of symptoms (intermittent or persistent) rather than on the time of allergen exposure (seasonal or perennial). There had been no placebo-controlled, randomized, clinical trial of desloratadine (DL) in patients with persistent allergic rhinitis to date. OBJECTIVES: To assess the efficacy and safety of DL in patients with persistent allergic rhinitis based on the ARIA classification. METHODS:Patients 12 years of age and older with persistent allergic rhinitis were assessed over 85 days of treatment with DL 5 mg once daily (n = 360) or placebo (n = 356). The primary endpoint was the AM/PM reflective total 5-symptom score (T5SS) averaged over days 1-29. Secondary endpoints included AM/PM instantaneous T5SS and individual symptoms, therapeutic response, symptom severity assessed by a visual analogue scale and quality of life. RESULTS: The mean reduction in AM/PM reflective T5SS was significantly greater with DL than placebo over days 1-29 (-3.76 vs. -2.87, p < 0.001) and on each individual day (p < 0.05). The mean AM instantaneous T5SS was significantly reduced with DL compared with placebo as early as day 2 (-1.90 vs. -1.46; p < 0.001). The therapeutic response and improvement in quality of life were significantly greater with DL than placebo (p < 0.001 for each). The frequency of treatment-related adverse events was low and similar between DL (10.0%) and placebo (8.4%). CONCLUSIONS: This study showed DL to be effective and safe in the treatment of persistent allergic rhinitis.
Authors: D J Costa; P Marteau; M Amouyal; L K Poulsen; E Hamelmann; M Cazaubiel; B Housez; S Leuillet; M Stavnsbjerg; P Molimard; S Courau; J Bousquet Journal: Eur J Clin Nutr Date: 2014-02-26 Impact factor: 4.016
Authors: J Bousquet; P W Hellings; I Agache; A Bedbrook; C Bachert; K C Bergmann; M Bewick; C Bindslev-Jensen; S Bosnic-Anticevitch; C Bucca; D P Caimmi; P A M Camargos; G W Canonica; T Casale; N H Chavannes; A A Cruz; G De Carlo; R Dahl; P Demoly; P Devillier; J Fonseca; W J Fokkens; N A Guldemond; T Haahtela; M Illario; J Just; T Keil; L Klimek; P Kuna; D Larenas-Linnemann; M Morais-Almeida; J Mullol; R Murray; R Naclerio; R E O'Hehir; N G Papadopoulos; R Pawankar; P Potter; D Ryan; B Samolinski; H J Schunemann; A Sheikh; F E R Simons; C Stellato; A Todo-Bom; P V Tomazic; A Valiulis; E Valovirta; M T Ventura; M Wickman; I Young; A Yorgancioglu; T Zuberbier; W Aberer; C A Akdis; M Akdis; I Annesi-Maesano; J Ankri; I J Ansotegui; J M Anto; S Arnavielhe; A Asarnoj; H Arshad; F Avolio; I Baiardini; C Barbara; M Barbagallo; E D Bateman; B Beghé; E H Bel; K S Bennoor; M Benson; A Z Białoszewski; T Bieber; L Bjermer; H Blain; F Blasi; A L Boner; M Bonini; S Bonini; I Bosse; J Bouchard; L P Boulet; R Bourret; P J Bousquet; F Braido; A H Briggs; C E Brightling; J Brozek; R Buhl; C Bunu; E Burte; A Bush; F Caballero-Fonseca; M A Calderon; T Camuzat; V Cardona; P Carreiro-Martins; A M Carriazo; K H Carlsen; W Carr; A M Cepeda Sarabia; M Cesari; L Chatzi; R Chiron; T Chivato; E Chkhartishvili; A G Chuchalin; K F Chung; G Ciprandi; J Correia de Sousa; L Cox; G Crooks; A Custovic; S E Dahlen; U Darsow; T Dedeu; D Deleanu; J A Denburg; G De Vries; A Didier; A T Dinh-Xuan; D Dokic; H Douagui; G Dray; R Dubakiene; S R Durham; G Du Toit; M S Dykewicz; P Eklund; Y El-Gamal; E Ellers; R Emuzyte; J Farrell; A Fink Wagner; A Fiocchi; M Fletcher; F Forastiere; M Gaga; A Gamkrelidze; B Gemicioğlu; J E Gereda; R Gerth van Wick; S González Diaz; I Grisle; L Grouse; Z Gutter; M A Guzmán; B Hellquist-Dahl; J Heinrich; F Horak; J O' B Hourihane; M Humbert; M Hyland; G Iaccarino; E J Jares; C Jeandel; S L Johnston; G Joos; O Jonquet; K S Jung; M Jutel; I Kaidashev; M Khaitov; O Kalayci; A F Kalyoncu; P Kardas; P K Keith; M Kerkhof; H A M Kerstjens; N Khaltaev; M Kogevinas; V Kolek; G H Koppelman; M L Kowalski; M Kuitunen; I Kull; V Kvedariene; B Lambrecht; S Lau; D Laune; L T T Le; P Lieberman; B Lipworth; J Li; K C Lodrup Carlsen; R Louis; C Lupinek; W MacNee; Y Magar; A Magnan; B Mahboub; D Maier; I Majer; J Malva; P Manning; E De Manuel Keenoy; G D Marshall; M R Masjedi; E Mathieu-Dupas; M Maurer; S Mavale-Manuel; E Melén; E Melo-Gomes; E O Meltzer; J Mercier; H Merk; N Miculinic; F Mihaltan; B Milenkovic; J Millot-Keurinck; Y Mohammad; I Momas; R Mösges; A Muraro; L Namazova-Baranova; R Nadif; H Neffen; K Nekam; A Nieto; B Niggemann; L Nogueira-Silva; M Nogues; T D Nyembue; K Ohta; Y Okamoto; K Okubo; M Olive-Elias; S Ouedraogo; P Paggiaro; I Pali-Schöll; S Palkonen; P Panzner; A Papi; H S Park; G Passalacqua; S Pedersen; A M Pereira; O Pfaar; R Picard; B Pigearias; I Pin; D Plavec; W Pohl; T A Popov; F Portejoie; D Postma; L K Poulsen; D Price; K F Rabe; F Raciborski; G Roberts; C Robalo-Cordeiro; F Rodenas; L Rodriguez-Mañas; C Rolland; M Roman Rodriguez; A Romano; J Rosado-Pinto; N Rosario; M Rottem; M Sanchez-Borges; J Sastre-Dominguez; G K Scadding; N Scichilone; P Schmid-Grendelmeier; E Serrano; M Shields; V Siroux; J C Sisul; I Skrindo; H A Smit; D Solé; T Sooronbaev; O Spranger; R Stelmach; P J Sterk; T Strandberg; J Sunyer; C Thijs; M Triggiani; R Valenta; A Valero; M van Eerd; E van Ganse; M van Hague; O Vandenplas; L L Varona; B Vellas; G Vezzani; T Vazankari; G Viegi; T Vontetsianos; M Wagenmann; S Walker; D Y Wang; U Wahn; T Werfel; B Whalley; D M Williams; S Williams; N Wilson; J Wright; B P Yawn; P K Yiallouros; O M Yusuf; A Zaidi; H J Zar; M E Zernotti; L Zhang; N Zhong; M Zidarn Journal: Clin Transl Allergy Date: 2016-12-30 Impact factor: 5.871
Authors: Ludger Klimek; Karl-Christian Bergmann; Tilo Biedermann; Jean Bousquet; Peter Hellings; Kirsten Jung; Hans Merk; Heidi Olze; Wolfgang Schlenter; Philippe Stock; Johannes Ring; Martin Wagenmann; Wolfgang Wehrmann; Ralph Mösges; Oliver Pfaar Journal: Allergo J Int Date: 2017-01-19
Authors: Nikolaos G Papadopoulos; Ioana Agache; Sevim Bavbek; Beatrice M Bilo; Fulvio Braido; Victoria Cardona; Adnan Custovic; Jan Demonchy; Pascal Demoly; Philippe Eigenmann; Jacques Gayraud; Clive Grattan; Enrico Heffler; Peter W Hellings; Marek Jutel; Edward Knol; Jan Lötvall; Antonella Muraro; Lars K Poulsen; Graham Roberts; Peter Schmid-Grendelmeier; Chrysanthi Skevaki; Massimo Triggiani; Ronald Vanree; Thomas Werfel; Breda Flood; Susanna Palkonen; Roberta Savli; Pia Allegri; Isabella Annesi-Maesano; Francesco Annunziato; Dario Antolin-Amerigo; Christian Apfelbacher; Miguel Blanca; Ewa Bogacka; Patrizia Bonadonna; Matteo Bonini; Onur Boyman; Knut Brockow; Peter Burney; Jeroen Buters; Indre Butiene; Moises Calderon; Lars Olaf Cardell; Jean-Christoph Caubet; Sevcan Celenk; Ewa Cichocka-Jarosz; Cemal Cingi; Mariana Couto; Nicolette Dejong; Stefano Del Giacco; Nikolaos Douladiris; Filippo Fassio; Jean-Luc Fauquert; Javier Fernandez; Montserrat Fernandez Rivas; Marta Ferrer; Carsten Flohr; James Gardner; Jon Genuneit; Philippe Gevaert; Anna Groblewska; Eckard Hamelmann; Hans Jürgen Hoffmann; Karin Hoffmann-Sommergruber; Lilit Hovhannisyan; Valérie Hox; Frode L Jahnsen; Omer Kalayci; Ayse Füsun Kalpaklioglu; Jörg Kleine-Tebbe; George Konstantinou; Marcin Kurowski; Susanne Lau; Roger Lauener; Antti Lauerma; Kirsty Logan; Antoine Magnan; Joanna Makowska; Heidi Makrinioti; Paraskevi Mangina; Felicia Manole; Adriano Mari; Angel Mazon; Clare Mills; Ervinç Mingomataj; Bodo Niggemann; Gunnar Nilsson; Markus Ollert; Liam O'Mahony; Serena O'Neil; Gianni Pala; Alberto Papi; Gianni Passalacqua; Michael Perkin; Oliver Pfaar; Constantinos Pitsios; Santiago Quirce; Ulrike Raap; Monika Raulf-Heimsoth; Claudio Rhyner; Paula Robson-Ansley; Rodrigo Rodrigues Alves; Zeljka Roje; Carmen Rondon; Odilija Rudzeviciene; Franziska Ruëff; Maia Rukhadze; Gabriele Rumi; Cansin Sackesen; Alexandra F Santos; Annalisa Santucci; Christian Scharf; Carsten Schmidt-Weber; Benno Schnyder; Jürgen Schwarze; Gianenrico Senna; Svetlana Sergejeva; Sven Seys; Andrea Siracusa; Isabel Skypala; Milena Sokolowska; Francois Spertini; Radoslaw Spiewak; Aline Sprikkelman; Gunter Sturm; Ines Swoboda; Ingrid Terreehorst; Elina Toskala; Claudia Traidl-Hoffmann; Carina Venter; Berber Vlieg-Boerstra; Paul Whitacker; Margitta Worm; Paraskevi Xepapadaki; Cezmi A Akdis Journal: Clin Transl Allergy Date: 2012-11-02 Impact factor: 5.871